Clinical and molecular prognostic factors in follicular lymphoma.
The observed variability in the clinical course of follicular lymphoma (FL), along with the diverse range of therapeutic options available, necessitates accurate prognostic stratification of the individual patient. A number of clinical, laboratory, and pathologic parameters have been associated with both good and poor risk disease; in some instances these have been incorporated into readily calculable prognostic indices. With new insights into disease biology and the resulting identification of biomarkers that have arisen from the analysis of both the genome and the transcriptome, more accurate individualization of prognosis will be realized. At present the clinical application of such biomarkers, however, remains largely in its infancy. This review examines the clinical and molecular prognostic features that have been identified as of value in FL.
Davies
Andrew J
AJ
Department of Medical Oncology, St Bartholomew's Hospital, West Smithfield, London, UK. Andrew.J.Davies@cancer.org.uk
D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D006801:Humans; D008224:Lymphoma, Follicular / Q000175:diagnosis* / Q000401:mortality* / Q000473:pathology; D011379:Prognosis
D014408:Biomarkers, Tumor